EXPOSOMICS

Final Policy Workshop and Stakeholder Consultation

28-29 March 2017 at

Borschette Conference Centre, European Commission, Rue Froissart 36, Brussels (Day 1)

&

Minerva Room, Hotel Chambord, rue de Namur 82, 1000 Brussels (Day 2)

Agenda

Tuesday 28th March 2017

"EXPOSOMICS" for hazard identification and risk assessment

Morning session

09:00 - 09:30 Welcome from the European Commission –
Arnd Hoeveler and Tuomo Karjalainen , DG Research and Innovation, Health Directorate, Brussels
Frauke Hoss, DG Environment, Quality of Life Directorate, Brussels

09:30 - 10:00 EXPOSOMICS: relevance to hazard identification and risk assessment
Paolo Vineis, Coordinator of Exposomics, Imperial College London

10:00 - 10:30 HELIX[1]: state of advancement and complementarities with EXPOSOMICS
Martine Vrijheid, Coordinator, HELIX Project, ISGlobal, Barcelona

10:30 - 10:55 How EXPOSOMICS has advanced the science of exposure assessment
John Gulliver, Imperial College London

[1] HELIX -*The human early-life exposome – novel tools for integrating early-life environmental exposures and child health across Europe*. Project funded by European Commission's Seventh Framework Programme of Research under grant agreement no: 308333 - http://www.projecthelix.eu/

10:55 - 11:15	**Coffee break**
11:15 - 11:40	The science of water contamination: contribution of EXPOSOMICS ***Manolis Kogevinas, ISGlobal, Barcelona***
11:40 - 12:00	Overview of omic investigations, with focus on experimental studies ***Soterios Kyrtopoulos, National Hellenic Research Foundation, Athens***
12:00 - 12:20	Overview of the Personal Exposure Monitoring (PEM) campaign ***Roel Vermeulen, Institute for Risk Assessment Sciences at Utrecht University***
12:20 - 13:20	**Lunch**

Afternoon session

13:20 - 14:05	Keynote address – The 21st Century Risk Assessment report of the US National Academy of Sciences ***Jon Samet, University of South California, Los Angeles***
14:05 - 15:05	**Plenary 1 - Internal exposome** (Plenary 1 questions on page 4)
15:05 - 15:35	What we have learnt about asthma and cardiovascular disease ***Nicole Probst-Hensch, Swiss Tropical and Public Health Institute, Basel***
15:35 – 16:05	What we have learnt on children's diseases ***Tim Nawrot, University of Hasselt***
16:05 - 16:20	**Coffee break**
16:20 - 16:50	Meet-in-the-middle, mixtures and longitudinal approaches to risk ***Marc Chadeau-Hyam, Imperial College London and Roel Vermeulen, Institute for Risk Assessment Sciences at Utrecht University***
16:50 – 17:35	Keynote address – New technologies for environmental health research ***David Phillips, King's College London***
17:35 - 18:30	**Plenary 2 - External exposome** (Plenary 2 questions on page 4)

Day 2 - Wednesday 29th March 2017 – Minerva Room, Hotel Chambord

From research to practice: How EXPOSOMICS and HELIX contribute to policies

Morning session

09:00 – 09:30 Exposome initiatives at the NIH/NIEHS
David Balshaw, National Institute of Environmental Health Sciences Research Triangle Park, North Carolina

09:30 - 10:30 **Plenary 3 - Policy translation**
(Plenary 3 questions on page 4)

10:30 - 10:45 **Coffee break**

Discussions: the future of the exposome

10:45 - 11:20 Weak carcinogens and "pathway perturbation"
Paolo Vineis, Imperial College London
Discussant: Tim Gant, Public Health England, London

11:20 - 11:55 The new science of exposure assessment
Mark Nieuwenhuijsen, ISGlobal, Barcelona
Discussant: Gary Miller, Emory University, Atlanta

11:55 - 12:35 New developments of the "exposome" concept
Christopher Wild, International Agency for Research on Cancer, Lyon
Discussant: Marco Martuzzi, WHO, Bonn

12:35 - 12:55 Comments and feedback from the European Commission
Arnd Hoeveler, DG Research and Innovation, Brussels

12:55 - 13:20 Final remarks on behalf of the International Scientific Advisory Board (ISAB)
Roberto Bertollini, Former WHO Chief Scientist and Representative to the European Union, Brussels

End of the Meeting

Questions for plenary sessions

Plenary 1: Internal Exposome – Led by Paolo Vineis and Tim Gant

What can be the contribution of omic measurements in hazard identification and risk assessment?

What are the current limitations?

What are the most urgent needs in the field of omics research?

Plenary 2: External Exposome – Led by Roel Vermeulen and Gary Miller

What can be the contribution of exposure science to hazard identification and risk assessment?

What is the state of the art of new exposure measurement technologies?

What are the research needs?

Plenary 3: Policy Translation – Led by Chris Wild and David Balshaw

In the light of the philosophy expressed in the US NAS report on pathway perturbation, what is the potential contribution of the exposome paradigm?

How does it fit into the strategies of environmental and public health agencies, NGOs, regulatory agencies, industry and academy? What institutional actors are necessary?

How should research be funded to meet the next challenges of exposome research?